Tag: Onyda xr

In May 2024, the U.S. Food and Drug Administration (FDA) approved Onyda XR, a liquid non-stimulant, for pediatric ADHD, making it one of the newest ADHD medication options available. This approval, alongside other emerging drugs in clinical trials, highlights the ongoing advancements in pharmacology aimed at expanding treatment choices.

The FDA approved Onyda XR, a liquid non-stimulant medication for ADHD, in 2024 for pediatric patients 6 years of age and older. For those considering this treatment, it is important to understand what are the side effects of the drug onyda? before beginning treatment.

As of late 2024, the U.S. Food and Drug Administration (FDA) approved Onyda XR, the first liquid non-stimulant ADHD medication for children and adolescents aged six years and older. This milestone is part of an expanding range of options for what is the new drug for ADHD, offering alternatives to traditional stimulant treatments and diverse formulations to fit individual needs.